Available evidence and outcome of off-label use of rituximab in clinical practice

European Journal of Clinical Pharmacology

Volumn 69, Issue 9, 2013, Pages 1689-1699

  Danes I ^a,b   Agusti A ^a,b   Vallano, A ^c,d   Martinez J ^a   Alerany, C ^a   Ferrer, A ^c   Lopez A ^a   Cortes Hernandez J ^a   Bosch, J A ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Drug therapy; Efficiency; Off label use; Pharmacy and therapeutics committees; Rituximab

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEMATOLOGIC DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; KIDNEY DISEASE; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEMBRANOUS GLOMERULONEPHRITIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELOOPTIC NEUROPATHY; NAUSEA; NEUTROPENIA; OFF LABEL DRUG USE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TERTIARY HEALTH CARE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CONNECTIVE TISSUE DISEASES; FEMALE; HEMATOLOGIC DISEASES; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; OFF-LABEL USE; TREATMENT OUTCOME;

EID: 84882919735     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1518-4     Document Type: Article

References (33)

1. Real Decreto 1015/2009, de 19 de junio, por el que se regula la disponibilidad de medicamentos en situaciones especiales. Boletín Oficial del Estado. Núm. 174 Lunes 20 de julio de 2009 Sec. I. Pág. 60904
2. CatSalut (2010) Instrucció 05/2010. Utilització de medicaments autoritzats en condicions diferents de les establertes en la fitxa tècnica. Available at: http://www10.gencat.cat/catsalut/archivos/ instruccions/instruccio-05-2010.pdf
3. Alerany C, Agustí A, Danés I, Martínez J, Fernández J, Bosch JA (2010) Com adaptar-nos a la nova normativa d'utilització de medicaments en situacions especials: un exemple d'iniciativa. e-farma;12. Available at: http://www10.gencat.net/catsalut/rsb/ farmacia/efarma/articles/adaptacio-nova-normativa-vhebron.pdf
4. Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47:115-123
5. European Medicines Agency. Mabthera: EPAR - product information. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000165/WC500025821.pdf
6. Gillis JZ, Dall'era M, Gross A, Yazdany J, Davis J (2007) Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 57:538-542
7. Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, Rémy P, Zarrouk V, Pillebout E, Jacquot C, Boffa JJ, Karras A, Masse V, Lesavre P, Elie C, Brocheriou I, Knebelmann B, Noël LH, Fakhouri F (2009) Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 4:579-587
8. Díaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martínez-Berriotxoa A, García-Hernández F, Callejas-Rubio JL, Rascón J, D'Cruz D, Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA, UK-BIOGEAS Registry (2012) Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 11:357-364
9. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE, Club Rhumatismes et Inflammation (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62:2458-2466
10. Trachana M, Koutsonikoli A, Farmaki E, Printza N, Tzimouli V, Papachristou F (2011) Safety and efficacy of Rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int. doi: 10.1007/s00296-011-2239-6
11. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA (2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18:767-776
12. Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Pérez-Alvarez R, Micó ML, Medrano F, de laTorre Gómez R, Díaz-Lagares C, Camps M, Ortego N, Sánchez-Román J, BIOGEAS Study Group (2010) Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 28:468-476
13. Butterly SJ, Pillans P, Horn B, Miles R, Sturtevant J (2010) Off-label use of rituximab in a tertiary Queensland hospital. Int Intern Med J 40:443-452
14. Van Allen EM, Miyake T, Gunn N, Behler CM, Kohlwes J (2011) Off-label use of rituximab in a multipayer insurance system. J Oncol Pract 7:76-79
15. Conde García MC, Fernández Feijoo MA, Calleja Hernández MA (2009) Estudio de adecuación a la ficha técnica, efectividad, seguridad y coste del rituximab en un hospital de tercer nivel. Farm Hosp 33:305-311
16. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586
17. Oxford Centre for Evidence-based Medicine (2009) Levels of evidence. Available at: http://www.cebm.net/?o=1025. Accessed 12 Sept 2012
18. U.S. National Institutes of Health. Clinicaltrials.gov. Available at: http://clinicaltrials.gov/ct2/home Accessed 12 Sept 2012
19. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99:706-714
20. Robak T, Dmoszynska A, Solal-Céligny P, Zyuzgin I, Ganly PS, Dartigeas C, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756-1765
21. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
22. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126
23. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391
24. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH (2012) Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367:520-531
25. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222-233
26. Narváez J, Ríos-Rodríguez V, de la Fuente D, Estrada P, López-Vives L, Gómez-Vaquero C, Nolla JM (2011) Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum 41:364-372
27. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, LUNAR Investigator Group (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64:1215-1226
28. Lightstone L (2012) The landscape after LUNAR: Rituximab's crater-filled path. Arthritis Rheum 64:962-965
29. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, Campagna S, Ferrara F, Angelucci E, Usala E, Cantoni S, Visani G, Fornaro A, Rizzi R, De Stefano V, Casulli F, Battista ML, Isola M, Soldano F, Gamba E, Fanin R (2010) Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 115:2755-2762
30. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146:25-33
31. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH (2009) Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 4:734-744
32. Hampton T (2007) Experts weigh in on promotion, prescription of off-label drugs. JAMA 297:683-684
33. American Cancer Society. Off-label drug use. Available at: http://www.cancer.org/Treatment/TreatmentsandSideEffects/TreatmentTypes/ Chemotherapy/off-label-drug-use. Accessed 11 Nov 2012